Diffusive by nature, glioma challenges clinical care by the impossibility of complete surgical resection of tumor, leaving the radio-and chemoresistant cells responsible for recurrence intact. We identified mammary- 
Introduction
Gliomas constitute approximately 30% of all primary nervous system tumors and 80% of all malignant brain tumors (1) . Glioblastoma is the most frequent, aggressive, and lethal type of gliomas. Glioblastomas harbor a dense abnormal vasculature, display large hypoxic and necrotic areas, and contain extensively proliferating tumor cells with the intrinsic ability to disseminate and colonize the brain far beyond the primary tumor mass. The current standard of care, comprising surgery, radio-and chemotherapy, provides only modest improvement in the patient survival, and the prognosis remains dismal (2) . This is due to (i) impossibility of complete surgical resection of the tumor; (ii) intratumoral heterogeneity and presence of multidrug-resistant cells and stem cell-like glioma cells responsible for the tumor maintenance and relapse, and (iii) the sheltering effect of the blood-brain-barrier (BBB), which efficiently prevents administration of many systemic anti-cancer agents into the brain. Most probably different approaches are required to eradicate the invasive cells and the cells that reside within the tumor bulk (3) . Thus, novel therapeutic approaches for glioblastomas are urgently needed (4).
We have previously identified mammary-derived growth inhibitor (MDGI) as a glioma biomarker expressed in tumor cells and their associated vasculature (5) . MDGI, also known as heart-type fatty acid binding protein (H-FABP/FABP3), belongs to the family of fatty acid binding proteins (FABPs) that facilitate the intracellular transport of fatty acids (6) . Both tumor-suppressive (7) and tumor-promoting (8, 9) functions, depending on the cancer type, have been reported for MDGI. In glioma cells, MDGI has been found to mediate lipid droplet formation and palmitate uptake (10) .
Here, we used cohorts of patients operated for a primary glioma and novel patient-derived human tumoroid cultures to examine the function of MDGI. MDGI was abundantly expressed in clinical gliomas, where its expression was associated with poor survival of patients. MDGI was upregulated by hypoxia and its overexpression enhanced the invasive growth of glioma cells both in vitro and in vivo. Surprisingly, MDGI silencing compromised tumoroid growth and glioma cell survival via lysosomal membrane permeabilization (LMP). Accordingly, we show that glioma cells were more sensitive than normal cells to an LMP inducing drug, the anti-histamine clemastine, in vitro and that clemastine treatment was able to eradicate the invasive glioma cells in vivo. Our results suggest that MDGI expression is crucial for glioma cell viability and an important regulator of lysosomal integrity. These characteristics make MDGI a potential therapeutic target and LMP-inducing drugs a promising treatment option to eradicate especially the invasive glioma cells.
Results

High MDGI expression correlates with poor survival
Our previous results show that MDGI is highly expressed in glioblastomas (5) Tables S1-2) . Only 5% of all gliomas (n = 6/122) lacked detectable MDGI expression. In the glioblastoma specimens, MDGI expression correlated with the presence of the CD117/C-Kit-receptor in the perinecrotic tumor regions (P=0.006) (Appendix Table S2 ). No association was detected between MDGI expression and EGFR (p>0.999), EGFRvIII (P=0.613), phosphorylated EGFR (Tyr-1173) (p>0.999) or p53 (P=0.499) (Appendix Table S2 ). Among the lower grade gliomas, MDGI expression did not correlate with the sex, tumor grade or the WHO 2007 histological type (p > 0.5; Appendix Table S1 ).
Moderate to high MDGI levels significantly associated both with poor glioma (grade II-III) -specific (HR = 1.85; 95% CI: 1.08-3.16; P=0.022; Appendix Figure S1A ) and poor overall survival of patients (HR = 1.98; 95% CI: 1.19-3.28; P=0.007, Figure 1A ) as compared to patients with negative or low tumor MDGI expression. Multivariable Cox hazards analysis showed that both MDGI expression and high tumor grade were independently associated with unfavorable overall survival, increasing the risk of death by the factor of 5 2 (Table 1) . In glioblastomas, tumor MDGI levels were not associated with overall survival (Appendix Figure S1B ). In addition to the patient tissue biopsies, MDGI expression was high in seven distinct patientderived tumoroid cultures, whereas it was low in all five adherent cell lines studied ( Figure 1B ).
MDGI overexpression promotes glioma cell invasion
Our immunohistochemical results in clinical tumor samples revealed a correlation between MDGI expression and perinecrotic C-Kit, which is an indirect hypoxia marker in glioblastomas (11) . In patientderived BT12 and BT13 tumoroids, MDGI expression was high in conjunction with strong expression of hypoxia-inducible factor 1 α (HIF-1α) regardless of the culture condition under normoxia or hypoxia ( Figure   1C ). However, serum-containing medium, which shifted the HIF-1α expressing hypoxic tumoroids to adherent monolayer growth, reduced both MDGI and HIF-1α levels ( Figure 1D ). Moreover, MDGI expression was highly increased by hypoxia in adherent cell lines ( Figure 1E ), linking MDGI induction in glioma cells closely to hypoxia.
As MDGI expression was associated with poor prognosis in the glioma patient cohort, we studied its function in glioma cell growth and invasion. We overexpressed MDGI as a GFP-fusion protein (MDGI-GFP) in the U87MG cells since they express low endogenous levels of MDGI and form local, non-invasive tumors following intracranial injection in pre-clinical models. While MDGI overexpression did not affect cell proliferation (Appendix Figure S1C) , it significantly enhanced colony formation, suggesting an increased capacity for aggressive, anchorage-independent growth of the MDGI overexpressing cells (Figure   2A -B). In addition, MDGI overexpressing tumoroids grew more invasively in an ex vivo brain slice model compared to the control cells ( Figure 2C-D) . Moreover, the intracranial U87MG-MDGI-GFP xenografts grew invasively ( Figure 2E-F) , formed satellite tumors in the brain ( Figure 2G -H, K), and displayed vascular co-option ( Figure 2I -J, L) unlike the control GFP-expressing U87MG derived xenografts that, as expected, only formed cyst-like delineated masses.
MDGI silencing dramatically reduces glioblastoma cell viability
To confirm MDGI´s importance in aggressive cell growth, we silenced MDGI in in patient-derived BT12 and BT13 glioblastoma cells using shRNA (shMDGI1). Efficient gene silencing was verified using Western blot analysis (Appendix Figure S1D) . MDGI silencing caused a dramatic change in the cell morphology and disappearance of the large multicellular tumoroids ( Figure 3A) . Moreover, the anchorage-independent growth of the MDGI silenced cells was severely compromised ( Figure 3B) . Surprisingly, MDGI silencing inhibited proliferation of both BT12 and BT13 cells ( Figure 3C ) and dramatically reduced their viability ( Figure 3D ). Similar, but slightly less drastic effects were obtained with another shRNA-construct (shMDGI2) with approximately 70-80% knockdown efficiency (Appendix Figure S1E -G and S2A-B); demonstrating a dose-dependent effect of MDGI silencing on glioblastoma cell growth and viability. Next, we studied whether MDGI silencing induced cell death was affected by the EGFR expression, since EGFR is mutated, amplified, or both in about 60% of glioblastomas. Only the patient-derived glioblastoma BT11, BT12, and BT13 tumoroids expressed high levels of EGFR, while expression was low in U87MG and LN308 cells ( Figure 3E ). No EGFR expression was detected in other cell lines studied ( Figure 3E ). MDGI silencing induced death also of the ZH305 tumoroids that did not express EGFR indicating that EGFR status of glioma cells did not affect their sensitivity to LMP ( Figure 3F -G).
MDGI silencing induces caspase-independent glioma cell death
To further examine the mechanism underlying the reduced viability of MDGI silenced cells, we studied the binding of Annexin V to the exposed phosphatidylserines as a marker of cell death (12) . We observed significantly increased binding of Annexin V to the MDGI silenced cells indicating increased cell death ( Figure 4A -B and Appendix Figure S2C-D) . To study the intracellular pathways that could contribute to this increased cell death, we analyzed the expression of apoptosis-associated proteins ( Figure 4C and Appendix Figure S2E ) at various time points after lentiviral MDGI silencing. Expression of the phosphorylated and total p53 as well as the pro-apoptotic protein BAD remained first stable and were eventually decreased 5-6 days after transduction ( Figure 4C and Appendix Figure S2E) . Surprisingly, the amounts of total caspase 3 and its cleaved, activated form were also decreased 5-6 days after silencing ( Figure 4C and Appendix Figure   S2E ). This suggests that apoptosis in the MDGI silenced cells was not mediated by the caspase activation.
To verify the results, we next performed an antibody array of apoptosis-associated proteins using extracts of control and MDGI silenced cells. When fold-changes less than 0.6 or more than 1.5 compared to control was used as cut-offs, levels of the anti-apoptotic survivin and X-linked inhibitor of apoptosis protein (XIAP) were decreased. On the other hand, the protein levels of the HTRA serine protease were elevated (Appendix Figure S3A-B) . The levels of various caspases, pro-apoptotic proteins BAD and BAX or cytochrome C were not changed by MDGI silencing (Appendix Figure S3A-B) . Furthermore, MDGI silencing-induced cell death could not be rescued by silencing of the pro-apoptotic protein BAD by siRNA (Appendix Figure S3C-D) .
We also studied the expression of selected proteins of the key signaling pathways at different time points after MDGI silencing using Western blot ( Figure 4D and Appendix Figure S2F ). In MDGI silenced cells, p27 levels were elevated and the Erk1/2 phosphorylation was significantly induced, while the phosphorylated AKT was decreased ( Figure 4E and Appendix Figure S2F ) already at day three after silencing.
MDGI silencing induces lysosomal membrane permeabilization (LMP)
Since apoptosis in MDGI silenced cells seemed not to be mediated by caspase activation, and their phenotype could not be rescued by silencing of the pro-apoptotic protein BAD, we studied the effects of MDGI silencing on LMP. This alternative cell death pathway leads to the release of lysosomal hydrolases into the cytosol and can, depending on the extent of the release, ultimately lead to lysosomal cell death with necrotic or apoptotic features (13) . LMP induction can be easily visualized as a change in galectin-1 localization from a diffuse cytoplasmic to a punctate staining pattern (14) . As a control, we first treated the tumoroids with the LMP-inducing agent, L-leucine O-methyl (LLOMe) (15) , and detected increased formation of galectin-1 (LGALS1) -positive puncta ( Figure 5A 
Discussion
There is an unmet need for novel therapeutic strategies to treat gliomas making the characterization of proteins involved in disease progression highly important. Here we examined the expression of a potential glioma biomarker, MDGI (5), in clinical grade II-III glioma and glioblastoma specimens as well as in patient-derived and commercially available glioma cell lines. We show that high MDGI expression associated with unfavorable patient survival and was crucial for glioma cell viability. We further describe a novel function for MDGI in the maintenance of lysosomal membrane integrity and provide data that shows the exceptional vulnerability of invasive glioma cells to destabilization of lysosomes.
MDGI was frequently expressed in human gliomas and showed a significant correlation with poor survival.
High MDGI expression was also detected in various patient-derived, cancer stem cell-enriched tumoroids but not in adherent cells under normoxia. However, hypoxia could stimulate MDGI expression in adherent cells. This is in agreement with previous data that showed upregulation of MDGI expression during hypoxia (10) .
MDGI expression in adherent glioma cells significantly promoted their anchorage-independent growth and invasion both in vitro and in vivo, suggesting a functional role for MDGI in the invasive growth. Although MDGI expression has been linked to tumor suppressive properties in breast cancer (7), in gastric carcinomas MDGI associated with poor patient survival (8) and in melanomas its expression was upregulated during disease progression (9) suggesting that the effect of MDGI on tumorigenesis may be tissue and cancer typedependent.
Interestingly, our results demonstrate that MDGI expression is crucial for glioma cell survival. One of the central genes promoting glioblastoma cell survival is EGFR (17) . It addition, breast cancer cell resistance to EGFR targeted therapy has been shown to be mediated by MDGI (18) . However, it appears that the cell death induced by MDGI silencing is independent of the EGFR status of glioma cells. The ZH305 cells that do not express EGFR show the similar drastic loss of cell viability after MDGI silencing when compared to the BT12 and BT13 tumoroids expressing high amounts of EGFR. In addition, we observed significantly increased LMP in the MDGI silenced cells. LMP is a cell death pathway that leads inevitably to cell death due to irreversible leakage of lysosomal enzymes to the cytoplasm, where they digest vital proteins and intracellular organelles (13) . Due to MDGI's fatty acid binding and transport ability, it is possible that its silencing may lead to alterations in the lysosomal membrane composition. Previous report showed that incorporation of arachidonic acid and choline glycerophospholipid into phospholipid membranes is reduced in the MDGI knockout mice (19) . In addition, activation of Erk in the MDGI silenced cells could play a role in the process, since phosphorylated Erk -besides being linked to apoptosis-induction and cell cycle arrest (20) -has also been shown to enhance cysteine cathepsin expression and activity, sensitizing cells to LMP (21) . In addition to the LMP, we also observed decreased activity of the AKT kinase (the master regulator of various cell survival pathways (22)), downregulation of anti-apoptotic proteins XIAP and survivin, which has been linked to caspase-independent apoptosis (23) as well as an upregulation of the pro-apoptotic serine protease HTRA (24) and cyclin-dependent kinase inhibitor p27/Kip1, a negative regulator of the cell cycle (25) . HTRA has been shown to contribute to cell death by downregulating XIAP protein levels (26) and decrease chemoresistance of colon cancer cells (27) (28, 29) . LMP induction in glioblastoma treatment has not been widely studied, but several studies have recently characterized the mechanism of action of some novel chemotherapeutics and shown that lysosomal dysfunction plays a major role in drug-mediated cancer cell death (30) (31) (32) . Among the drugs currently on the market, cationic amphiphilic (CAD) anti-histamines induce lysosomal cell death. Moreover, use of the CAD antihistamines was associated with significantly reduced all-cause mortality among cancer patients when compared with the use of non-CAD antihistamines and adjusted for potential confounders (16) . We chose an older generation CAD anti-histamine, clemastine, due to its ability to cross the BBB, to test the sensitivity of our patient-derived glioblastoma cells towards LMP induction. Clemastine is devoid of neurotoxic effects (33) even though it causes reported fatigue-induced side effects common to most of the anti-histamine drugs (34) . It has been shown to exert regenerative properties on the optic nerve (35) , induce re-myelinization (36) and temper down inflammation (37) in amyotrophic lateral/multiple sclerosis preclinical models. Moreover, clemastine is FDA-approved and currently under clinical evaluation for the above mentioned neurodegenerative disease (38) . We observed a dramatic loss of the glioblastoma cell viability that was associated with the loss of lysosomal membrane (40) . The resistance of the tumor bulk towards clemastine may also be due to the chemoattraction of glioma cells to subventricular/intraventricular space (41) that was observed in some of our animals or the extreme resistance of glioma cells when part of a connective network compared to single cells (42) .
Many triggers of the LMP are known (13, 43, 44) , but genes and cellular pathways that regulate the lysosomal membrane integrity remain poorly understood. Our study demonstrates the crucial role of MDGI in glioma cell survival and its involvement in the LMP, suggesting a novel role for MDGI in maintaining lysosomal membrane integrity. A very recent study by Guishard et al. showed the existence of an evident translational gap in the past and ongoing clinical glioma trials due to the lack of attempts to include drugs that are able to cross the BBB and overcome the chemoresistance of glioma stem cells (3). The inoperable and highly invasive and chemo-resistant glioma stem cell -like cells showed an unexpected fragility towards LMP. Thus, providing a potential answer to the clinical challenge of the management of the cells that eventually will lead to the recurrence of the disease. These results also suggest re-positioning of an old drug with a new indication. More widely, LMP-inducing agents should be considered as a possible novel treatment option for gliomas.
Materials and methods
Glioma patient series
The glioblastoma and grade II-III glioma patient biopsies were obtained from the Department of Pathology, Helsinki University Hospital, Finland. The series have been described elsewhere (45, 46) . Briefly, glioblastoma TMA was composed of formalin-fixed paraffin embedded (FFPE) tumors derived from 43 craniotomy patients, subsequently diagnosed with primary glioblastoma between October 2000 and December 2003. The median survival time of the patients was 9 months (range 1-40 months) as calculated from the date of the diagnosis to the date of death. All patients died due to glioblastoma during follow-up. In seven cases, tissue microarray sample was missing or staining was not informative leaving 36 patients in the series.
FFPE grade II-III glioma TMAs were prepared from the tumors of 122 patients who were operated for a primary glioma at the Helsinki University Hospital between 1979 to 2000. In ten cases, tissue microarray sample was missing or staining was not informative leaving 112 patients for the analysis. 33 of the tumors (30%) were diagnosed as astrocytoma, 16 (14%) as anaplastic astrocytoma, 36 (32%) as 13 glioblastoma, 18 (16%) as oligodendroglioma and 9 (8%) as oligoastrocytoma. The association of MDGI with clinical and histopathological factors was studied from 76 low-grade samples, excluding glioblastoma patients and the median follow-up time after surgery was 6.0 years (range 0.6-17.0 years). Ten of the patients lived at the end of the follow-up, while 58 and 8 patients died from glioma or other causes, respectively.
Immunohistochemistry and evaluation of immunostaining
The detailed protocol is found in Appendix Supplementary Material. MDGI expression was evaluated blinded to the clinical data and scored as follows: 0, all tumor cells negative; 1, low expression in tumor cells (5% to 50%); 2, moderate expression in ≥50% of tumor cells; and 3, high expression in ≥50% of tumor cells.
For the statistical analyses, 0 and 1, as well as 2 and 3 tumors were grouped together. MDGI's vascular expression was scored as follows: 0, no MDGI-positive vessels; 1, one or more MDGI-positive vessels.
Patient-derived cells
The glioma patient samples were obtained from surgeries (Kuopio University Hospital, Finland) during years 2010-2011. BT5 cells were obtained from a human gliosarcoma and BT5R cells from its relapse. BT11 cells are from a glioblastoma-containing oligocomponents, BT12 and BT13 cells are from glioblastoma patients.
Protocol for the cell isolation can be found in the Appendix Supplementary Material.
Cell culture
The patient-derived brain tumor cells (BT11, BT12, BT13, BT5, BT5R) were maintained for up to 20 passages in Dulbecco's Modified Eagle Medium with Nutrient Mixture F-12 (DMEM/F12, Gibco) and patient-derived cell line ZH305 (generated at Zurich University Hospital) was maintained for up to 10 passages in phenol red-free Neurobasal medium (Invitrogen). Both media were supplemented with 2 mM Lglutamine, 2% B27-supplement (Gibco), 100 U/ml penicillin and 100 µg/ml streptomycin, 0.01 g/ml human fibroblast growth factor (FGF, Peprotech), 0.02 μg/ml human epidermal growth factor (EGF, Peprotech), and 15 mM HEPES-buffer. All the cells were maintained and grown at 37 o C in a humidified 14 atmosphere containing 5% CO 2 unless stated otherwise. Mycoplasma contamination was routinely checked twice a month using the mycoplasma detection kit (11-1050, Minerva Labs). Additional information about the commercial cell lines can be found in the Appendix Supplementary Material.
Generation of MDGI silenced cells
The MDGI/FABP3 shRNA-constructs in the pLKO.1 vector were obtained from the RNAi Consortium shRNA library (Broad Institute of MIT and Harvard). The sequences were as follows: shMDGI1:
, shMDGI2:
. Lentivirus production and transduction protocol can be found in the Appendix Supplementary Material.
Anchorage-independent growth assay
Cells (3000/35-mm well, triplicates) were suspended in medium containing 0.35% agarose and pipetted into 6-well plates containing a 2-ml layer of solidified 0.7% agar in the medium. Complete medium was added twice a week. After 14 (U87MG) or 27 (BT12 and BT13) days, eight images per well were taken (Zeiss Axiovert) and the number of colonies was quantified using the ImageJ software (National Institute of Health, USA). The experiment was repeated twice.
Ex vivo brain slice cultures
Female FVB mice (5-8 weeks of age) were anesthetized and their brains were removed. Cerebellum was excised and the two hemispheres were embedded into 4% Low Melting Point Agarose (Thermo Scientific) in PBS. Slices of 500 μm were cut with a vibratome (HistoLab) and placed on top of 0.4 μm filter membranes (Millipore) in 6-well plates. Neurobasal A (1 ml, Gibco) supplemented with 1 mM glutamine, 2% B-27
(Gibco) and 1% penicillin/streptomycin was added to the bottom of each well. The medium was changed every other day. The slices were incubated for one week (37°C, 5% CO 2 ) before starting the experiments (47). The spheres were formed o/n in U-shaped 96-well plates coated with 0.6% agarose (4000 cells/well), after which they were placed to the brain slices. The GFP-fluorescent spheres were imaged at indicated time points by taking 10 μm optical slices with Leica TCS SP2 confocal microscope. Image stacks were generated using the ImageJ-software and the number of invaded and migrated cells/cell groups were quantified manually. The experiment was repeated twice with 3-5 individual spheres/cell line/slice in each experiment.
Analysis of lysosomal membrane permeabilization
LMP was determined using the LGALS1 puncta-staining assay (14) . BT12 
LMP induction by clemastine
Clemastine fumarate salt (Sigma) cytotoxicity was tested at the indicated concentrations and time points using the MTT protocol as described in the Appendix Supplementary Material. LMP induction by clemastine was verified using the LGALS1 puncta-staining assay described in the previous section (14) .
Animal experiments
Animal experiments were approved by the Committee for Animal Experiments of the District of Southern 
Statistics
Association of MDGI expression with other factors was tested using a Chi-squared test or Fisher's exact test and Mann-Whitney's U-test was used for the MDGI vs age analysis. All tests were 2-tailed. The cumulative survival rates of patients were estimated by using the Kaplan-Meier method, and survival between groups, hazard ratio (HR), and their 95% confidence interval (95% CI) were computed by using the Cox proportional hazards model. Overall survival was calculated from the date of the surgery of primary tumor to death, censoring patients still alive on the last date of follow-up. Glioma-specific survival was calculated from the date of the surgery of primary tumor to glioma caused death, censoring patients still alive or lost from follow-up for other cause on the last date of follow-up. Analyses were conducted with the IBM SPSS 22
software. Results from all other experiments were analyzed using the GraphPad Prism 7 software (La Jolla, USA) using two-tailed, nonparametric Mann-Whitney U test. All the experiments were repeated at least 3 times with triplicates unless stated otherwise.
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